Molecular information firm Courtagen Life Sciences has introduced 17 new gene tests for neurology and endocrinology.

The new products expand the company's Spotlight line of tests by around 65% in neurology, endocrinology, and other disease areas.

The new Spotlight tests are comprised of various pain-related panels such as migraine, neuropathic pain and abdominal pain.

It also includes endocrinology-related panels such as hyper/hypoglycemia (MODY+), hyperparathyroidism, and pituitary hormone deficiency.

New neurology panels are also added for neuromuscular disorders such as periodic paralysis, dystonia, and rhabdomyolysis.

According to the company, the new line also adds to the selection of tests currently available for epilepsy, developmental delay and mitochondrial disease.

Courtagen Life Sciences CEO Brian McKernan said: “This marks the first step in the expansion of our Spotlight tests – an important area of focus for Courtagen this year.

“In addition to new neurology tests, we are also moving into adjacent disease areas to address the overlapping symptoms we see in our patient population.”

Courtagen Life Sciences chief laboratory director Dr Christine Stanley said: “The smaller Spotlight tests are highly phenotype driven, providing a way for physicians to target the most clinically relevant genes for the symptoms displayed by their patients.”

Courtagen, which operates next generation DNA sequencing, bioinformatics and clinical interpretation business, focuses on the diagnosis of a range of neurological disorders.

Image: Courtagen has introduced 17 new Spotlight gene tests. Photo: courtesy of Suwit Ritjaroon /